Zelenectide Pevedotin Shows Early Activity in Advanced Nectin‑4–Expressing Tumors, With Promising Responses in Urothelial Carcinoma
First-in-human dose-escalation data for zelenectide pevedotin (BT8009), a Nectin‑4–targeted Bicycle Drug Conjugate, demonstrate tolerability and preliminary efficacy (ORR 24% overall; 38% in urothelial carcinoma) supporting further evaluation.